A
8.15
0.21 (2.64%)
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 看涨 |
| Biotechnology (全球的) | 混合的 | 看涨 | |
| 股票 | Achieve Life Sciences, Inc. | 混合的 | 看涨 |
AIStockmoo 评分
0.0
| 分析师共识 | NA |
| 内部交易活动 | -1.5 |
| 价格波动 | -4.0 |
| 技术平均移动指标 | 1.5 |
| 技术振荡指标 | 4.0 |
| 平均 | 0.00 |
|
Achieve Life Sciences Inc is a specialty pharmaceutical company committed to advancing cytisinicline as a widely available treatment option to help people battling nicotine addiction. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe. Achieve's focus is to address the smoking health epidemic through the development and commercialization of cytisinicline. It has one operating segment, dedicated to the development and commercialization of cytisinicline for niceon. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Growth |
| 内部持股比例 | 9.69% |
| 机构持股比例 | 41.59% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Venbio Partners Llc | 30 Jun 2026 | 5,914,720 |
| Propel Bio Management, Llc | 30 Jun 2026 | 4,034,018 |
该时间范围内无数据。
| 名称 | 平均购买 ($) | 平均卖出 ($) | 总净额 | 总净值 ($) |
|---|---|---|---|---|
| STEWART RICHARD ALISTAIR | - | 8.53 | -20,626 | -175,940 |
| 累积净数量 | -20,626 | |||
| 累积净值 ($) | -175,940 | |||
| 累积平均购买 ($) | - | |||
| 累积平均卖出 ($) | 8.53 | |||
| 名称 | 持有人 | 日期 | 类型 | 数量 | 价格 | 价值 ($) |
|---|---|---|---|---|---|---|
| STEWART RICHARD ALISTAIR | 董事 | 19 Aug 2026 | 卖 (-) | 20,626 | 8.53 | 175,940 |
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合